- Home
- UNCY vs HUMA Comparison
UNCY vs HUMA Comparison
Compare UNCY & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UNCY | HUMA |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | N/A | 184 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.3M | 155.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | UNCY | HUMA |
|---|---|---|
| Price | $8.12 | $1.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $25.67 | $6.19 |
| AVG Volume (30 Days) | 523.7K | ★ 6.2M |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $675,000.00 | N/A |
| Revenue This Year | N/A | $444.16 |
| Revenue Next Year | $582.86 | $248.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $0.55 |
| 52 Week High | $8.74 | $2.93 |
Technical Indicators
Market Signals| Indicator | UNCY | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 57.60 | 57.98 |
| Support Level | $5.95 | $0.92 |
| Resistance Level | $8.54 | $1.28 |
| Average True Range (ATR) | 0.44 | 0.13 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 55.04 | 57.32 |
Price Performance
Historical ComparisonAbout UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.